Filing Details

Accession Number:
0001181431-10-041137
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-08-10 13:00:00
Reporting Period:
2010-08-06
Filing Date:
2010-08-10
Accepted Time:
2010-08-10 14:12:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1356857 Trius Therapeutics Inc TSRX Pharmaceutical Preparations (2834) 201320630
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1456585 Versant Side Fund Iii, L.p. C/O Versant Ventures
3000 Sand Hill Road, Bldg. 4, Ste. 210
Menlo Park CA 94025
No No Yes No
1456586 Versant Venture Capital Iii, L.p. 3000 Sand Hill Road
Bldg. 4, Ste. 210
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-08-06 1,576,814 $0.00 1,576,814 No 4 C Indirect See footnotes
Common Stock Acquisiton 2010-08-06 744,496 $4.38 2,321,310 No 4 C Indirect See footnotes
Common Stock Acquisiton 2010-08-06 914,529 $5.00 3,235,839 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-2 Convertible Preferred Stock Disposition 2010-08-06 9,090,910 $0.00 9,090,910 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2010-08-06 4,469,697 $0.00 4,469,697 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Upon the closing of the Issuer's initial public offering, each 8.6 shares of the Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of Common Stock, and had no expiration date.
  2. The shares are held as follows: 1,567,556 shares held by Versant Venture Capital III, L.P. and 9,258 shares held by Versant Side Fund III, L.P.
  3. The Common Stock was acquired upon conversion of a Secured Convertible Promissory Note exempt from the definition of a derivative security and whose conversion ratio did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering. The shares are held as follows: 740,126 shares held by Versant Venture Capital III, L.P. and 4,370 shares held by Versant Side Fund III, L.P.
  4. The shares were purchased in the Issuer's initial public offering and are held as follows: 909,160 shares held by Versant Venture Capital III, L.P. and 5,369 shares held by Versant Side Fund III, L.P.
  5. The shares are held as follows: 9,037,534 shares held by Versant Venture Capital III, L.P. and 53,376 shares held by Versant Side Fund III, L.P.
  6. ) The shares are held as follows: 4,443,454 shares held by Versant Venture Capital III, L.P. and 26,243 shares held by Versant Side Fund III, L.P.
  7. In their capacity as managing members of Versant Ventures III, LLC, which is the general partner of each of the Versant Funds, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden and Barbara N. Lubash share voting and investment authority over the shares held by the Versant Funds and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden and Barbara N. Lubash disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.